ArticleCancer pathogenesis and therapy2026

Healthcare costs and health outcomes analysis of neoadjuvant Trastuzumab therapy for human epidermal growth factor receptor 2 (HER2) positive breast cancer.

Amirhossein Jalali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.